Experimental inhibition of protamine cardiotoxicity by prostacyclin

Angiology

Volumn 50, Issue 11, 1999, Pages 929-935

  Katircioǧlu, S Fehmi ^a   Ulus, Tulga ^a   Yamak, Birol ^a   Saritaş, Zülfikar ^b   Yildiz, Ülkü ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN; PROTAMINE;

ANIMAL EXPERIMENT; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; NONHUMAN;

EID: 0032748512     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331979905001108     Document Type: Article

References (31)

1. Morel DR, Zapol WM, Thomas SJ, et al: C5a and thromboxane generation associated with pulmonary vaso-and broncho-constriction during protamine reversal of heparin. Anesthesiology 66:597-604, 1987.
2. Michaels AL, Barash PG: Hemodynamic changes during protamine administration. Anesth Analg 62:831-835, 1983.
3. 2 receptor-specific antagonism in hypothermic cardiopulmonary bypass. Ann Thorac Surg 57:999-1006, 1994.
4. Katircioǧlu SF, Küçükaksu DS, Bozdayi M, et al: Effects of prostacyclin on heparin reversal with protamine. Vascular Surgery 26:464-472, 1992.
5. Katircioǧlu SF, Küçükaksu DS, Bozdayi M, et al: The beneficial effects of aminophylline administration on heparin reversal with protamine. Surg Today 24:99-102, 1994.
6. Lowenstein E, Johnston WE, Pappas DG, et al: Catastrophic pulmonary vasoconstriction associated with protamine reversal of heparin. Anesthesiology 59:470-473, 1983.
7. Katircioǧlu SF, Küçükaksu DS, Bozdayi M, et al: Beneficial effects of prostacyclin treatment on reperfusion of the myocardium. Cardiovasc Surg 3:405-408, 1995.
8. Judgett BF, Hutchins GM, Bulkley BH, et al: Infarct size reduction by prostacyclin after coronary occlusion in conscious dogs. Clin Res 27:177A, 1979.
9. Riberio LGT, Brandon TA, Hopkins DG, et al: Prostacyclin in experimental myocardial ischemia: Effects on hemodynamic regional myocardial blood flow, infarct size and mortality. Am J Cardiol 47:835-840, 1981.
10. Ohlendorf R, Perzborn E, Schrör K: Prevention of infarction-induced decrease in circulating platelet count by prostacyclin. Thromb Res 19:447-453, 1980.
11. Katircioǧlu SF, Küçükaksu DS, Küplülü S, et al: Effects of prostacyclin on spinal cord ischemia: An experimental study. Surgery 114:36-39, 1993.
12. Pohlman TH, Stanness KA, Beatty PG, et al: An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor α increases neutrophil adherence by a CDw 18-dependent mechanism. J Immunol 136:4548-4553, 1986.
13. Tsujimoto M, Yokota S, Vilcek J, et al: Tumor necrosis factor provokes superoxide anion generation from neutrophils. Biochem Biophys Res Commun 137:1094-1098, 1986.
14. Bevilacqua MP, Wheeler ME, Pober JS, et al: Endothelial-dependent mechanisms of leukocyte adhesion: Regulation by interleukin-1 and tumor necrosis factor. In: Leukocyte Emigration and Its Sequelae, ed. by Movat HZ. New York: Karger, 1979, p 179.
15. 4 generation and chemotaxis in human neutrophils. Arch Surg 123:1454-1458, 1988.
16. Shalby MR, Aggarwal BB, Rinderknecht E, et al: Activation of human polymorphonuclear neutrophil function by interferongamma and tumor necrosis factor. J Immunol 135:2069, 1985.
17. Horton JW, White DJ: Free radical scavengers prevent intestinal ischemia-reperfusion-mediated cardiac dysfunction. J Surg Res 55:282-289, 1993.
18. Pober JS, Cotran RS: Cytokines and endothelial cell biology. Physiol Rev 70:427-451, 1990.
19. De Mey JG, Vanhoutte PM: Heterogeneous behavior of the canine arterial and venous wall: Importance of the endothelium. Circ Res 51:439-447, 1982.
20. Aiken JW, Gorman RR, Shebuski RJ: Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation. Prostaglandins 17:483-494, 1979.
21. Rosenbaum D, Levitsky S, Silverman N, et al: Cardioplegia does not prevent reperfusion injury induced by intracoronary platelet deposition. Circulation 68 (suppl II):102-106, 1983.
22. Hattori R, Hamilton KK, McEver RPP, et al: Complement proteins C5b-9 induce secretion of high moleculer weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 264:9053-9060, 1989.
23. Lawrence MB, Springer TA: Leukocytes roll on a selectin at physiologic flow rates: Distinction from and prerequisite for adhesion through integrins. Cell 65:859-873, 1991.
24. Bevilacqua MP, Pober JS, Mendrick DL, et al: Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 84:9238-9242, 1987.
25. Palluy O, Morliere L, Griss JC, et al: Hypoxia/reoxygenation stimulated endothelium to promote neutrophil adhesion. Free Rad Biol Med 13:21-30, 1992.
26. Furchgott RF, Vanhouttte PM: Endothelium-derived relaxing and contracting factor. FASEB J 3:2007-2018, 1989.
27. Wakefield TW, Ucros I, Kresowik TF, et al: Decreased oxygen consumption as a toxic manifestation of protamine sulfate reversal of heparin anticoagulation. J Vasc Surg 9:772-777, 1989.
28. Neto MJA, Syhes MK, Marin DLB, et al: Effect of heparin and protamine left ventricular performance in the dog. Cardiovasc Res 13:254-259, 1979.
29. Fadali MA, Ledbetter M, Papacostas CA, et al: Mechanism responsible for the cardiovascular depressant effect of protamine sulfate. Ann Surg 180:232-235, 1974.
30. Frater RWM, Oka Y, Hang Y, et al: Protamine induced circulatory changes. J Thorac Cardiovasc Surg 87:687-699, 1984.
31. Horrow JC: Protamine: A review of its toxicity. Anesth Analg 64:348-361, 1985.